Drugs / Y150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05011097 | Jul 2021 → Oct 2023 | refractory plasma cell neoplasm | Wuhan YZY Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05011097 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT05011097 ↗ |
| Target | CD38 | “Anti-CD38” NCT05011097 ↗ |